Abstract
Purpose
Approximately 80 % of patients with prostate cancer will develop bone metastases, which often lead to bone pain and skeletal-related events. Sr-89 is an established alternative for the palliation of bone pain in prostate cancer. We aimed to assess the effect of Sr-89 radionuclide therapy on quality of life (QOL) in prostate cancer patients with painful bone metastases.
Materials and methods
Thirteen patients received a single intravenous injection of Sr-89 at a dose of 2.0 MBq/kg. All patients underwent QOL evaluation prior to Sr-89 treatment and 1, 2, and 3 months afterward using the Japanese version of the EORTC QLQ-BM22, EORTC QLQ-C30, a VAS, and face scale. We also evaluated PSA and ALP response and toxicity of the Sr-89 therapy.
Results
The pain characteristics subscale of the EORTC QLQ-BM22 was significantly reduced from 1 month onward compared with the baseline. The functional interference and psychosocial aspects subscales were significantly higher than baseline from 2 months onward. At 2 months, VAS indicated a significant reduction in pain as compared to the baseline. Sr-89 therapy caused a nonsignificant reduction in PSA and ALP levels. No patients had leukocyte toxicity, and one patient had grade 3 platelet toxicity.
Conclusion
Sr-89 radionuclide therapy can provide not only reduced pain characteristics but also better psychosocial aspects and functional interference in patients with painful bone metastases of prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
Henkin RE, Del Rowe JD, Grigsby PW, Hartford AC, Jadvar H, Macklis RM, et al. ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical Sources. Clin Nucl Med. 2011;36(8):e72–80.
Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43(1):79–86.
Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ, Mason MD, Quilty PM, et al. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. Semin Oncol. 1993;20(3 Suppl 2):32–3.
Chow E, Hird A, Velikova G, Johnson C, Dewolf L, Bezjak A, et al. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer. 2009;45(7):1146–52.
Chow E, Bottomley A. Understanding the EORTC QLQ-BM22, the module for patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):461–5.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.
Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17(6):1654–63.
Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006;24(18):2828–35.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.
Satoh T, Kobayashi K, Hori T, Iida S, Sato A, Ishiguro H, et al. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Japanese patients with bone metastases—The Japanese version of the EORTC QLQ-BM22. Gan To Kagaku Ryoho. 2010;37(8):1507–12.
Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574–81.
Chow E, Nguyen J, Zhang L, Tseng LM, Hou MF, Fairchild A, et al. International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer. 2012;118(5):1457–65.
Kuroda I. Effective use of strontium-89 in osseous metastases. Ann Nucl Med. 2011 (in press).
Yoshimura M, Saito K, Park J, Akata S, Koizumi K, Tokuue K, et al. Tumoricidal effect of strontium-89. Clin Nucl Med. 2011;36(4):296–9.
Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010;8(5):341–51.
Gunawardana DH, Lichtenstein M, Better N, Rosenthal M. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med. 2004;29(2):81–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kurosaka, S., Satoh, T., Chow, E. et al. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy. Ann Nucl Med 26, 485–491 (2012). https://doi.org/10.1007/s12149-012-0598-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-012-0598-z